scFv(HER2)-41BB-CD3zeta CAR-T Lentivirus

scFv(HER2)-41BB-CD3ζ CAR-T Lentivirus is a gene-delivery reagent developed to generate T cells with targeted recognition of human epidermal growth factor receptor 2 (HER2/ERBB2). The encoded second-generation chimeric antigen receptor contains an extracellular anti-HER2 single-chain variable fragment (scFv), membrane-anchoring elements, the 4-1BB (CD137) costimulatory domain, and the CD3ζ activation domain. The scFv binds cell-surface HER2 independently of major histocompatibility complex presentation, while CD3ζ initiates the primary activation signal following antigen engagement. The 4-1BB domain supplies an additional costimulatory signal associated with sustained T-cell activity, survival, and persistence. Lentiviral delivery supports efficient gene transfer and stable CAR expression in transduced T cells, offering a reliable platform for producing HER2-responsive effector cells for laboratory investigation.

This lentivirus is intended for research on HER2-directed cell therapy and the functional behavior of second-generation CAR-T cells. Transduced T cells can be evaluated for CAR expression, antigen-dependent activation, cytotoxicity, cytokine secretion, proliferation, memory phenotype, and response durability. HER2-high, HER2-low, and HER2-negative target cells may be compared to investigate antigen-density thresholds, selectivity, and possible on-target effects in cells with different receptor levels. The product is applicable to experimental models of HER2-expressing breast, gastric, ovarian, lung, and other solid tumors, using appropriate in vitro assays or preclinical systems. It can also support studies of repeated antigen exposure, T-cell exhaustion, tumor-cell resistance, immune escape, and suppression within the tumor microenvironment. In comparative CAR research, this 4-1BB-containing construct provides a useful benchmark for examining how costimulatory design influences expansion, metabolism, persistence, and antitumor function relative to first-generation or CD28-based receptors. Its ready-to-use lentiviral format helps streamline exploratory screening, mechanistic studies, and early-stage evaluation of combination strategies involving checkpoint blockade, targeted agents, or other immunomodulatory approaches.